{"id":214,"date":"2022-05-17T22:00:00","date_gmt":"2022-05-17T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=214"},"modified":"2025-09-06T13:08:06","modified_gmt":"2025-09-06T13:08:06","slug":"china-bd-deal-2022-kelun-biotech-and-msd-enters-a-935-million-usd-license-on-trop2-adc-skb-315","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2022\/214.html","title":{"rendered":"[China BD deal 2022] Kelun-Biotech and MSD enters a 1.41 billion USD license on \u00a0Claudin18.2 ADC SKB-315(MK-1200)"},"content":{"rendered":"\n<p>Announced Date: 2022-05-16 (May 16, 2022)<\/p>\n\n\n\n<p>Asset Name: SKB-315 (MK-1200) <\/p>\n\n\n\n<p>Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd, China)&nbsp;<\/p>\n\n\n\n<p>Licensee (Buyer): &nbsp;MSD (Merck &amp; Co., Inc. USA)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Antibody drug conjugate (ADC)&nbsp;<\/p>\n\n\n\n<p>Asset Target: \u00a0Claudin18.2<\/p>\n\n\n\n<p>Current Stage: <\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational ADC.<\/p>\n\n\n\n<p>Kelun-Biotech and MSD will also collaborate on the early clinical development of the investigational ADC.&nbsp;<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0$47 million,<\/p>\n\n\n\n<p>Milestone payments up to \u00a0$1.363 billion,<\/p>\n\n\n\n<p>Plus tiered royalties on net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Kelun-Biotech (Chinese Name: \u79d1\u4f26\u535a\u6cf0\uff09<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2022-05-16 (May 16, 2022) Asset Name: SKB-315 (MK-1200) Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun &hellip; <a title=\"[China BD deal 2022] Kelun-Biotech and MSD enters a 1.41 billion USD license on \u00a0Claudin18.2 ADC SKB-315(MK-1200)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2022\/214.html\"><span class=\"screen-reader-text\">[China BD deal 2022] Kelun-Biotech and MSD enters a 1.41 billion USD license on \u00a0Claudin18.2 ADC SKB-315(MK-1200)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-214","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=214"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/214\/revisions"}],"predecessor-version":[{"id":217,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/214\/revisions\/217"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}